Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML

Pediatric Blood and Cancer

Volumn 59, Issue 5, 2012, Pages 922-924

  Rochowski, Andrzej ^a,b   Olson, Susan B ^c   Alonzo, Todd A ^d   Gerbing, Robert B ^e   Lange, Beverly J ^f   Alter, Blanche P ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute myelogenous leukemia; Clones; Cytogenetics; Fanconi anemia; Sporadic AML

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER PATIENT; CANCER SUSCEPTIBILITY; CHILDHOOD LEUKEMIA; CHROMOSOME 13Q; CHROMOSOME 16; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 3Q; CHROMOSOME 7Q; CHROMOSOME DELETION; CHROMOSOME INVERSION; CYTOGENETICS; FANCONI ANEMIA; GENE FREQUENCY; GENETIC PREDISPOSITION; HOSPITALIZED CHILD; HUMAN; MONOSOMY 7; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TRISOMY 8;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; FANCONI ANEMIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE;

EID: 84866145727     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24168     Document Type: Article

References (14)

1. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 2010; 24: 101-122.
2. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood 2003; 101: 822-826.
3. Rosenberg PS, Alter BP, Ebell W. Cancer Risks in Fanconi Anemia: Experience of the German Fanconi Anemia (GEFA) Registry. Haematologica 2007; 93: 511-517.
4. Tamary H, Nishri D, Yacobovich J, et al. Frequency and natural history of inherited bone marrow failure syndromes: The Israeli Inherited Bone Marrow Failure Registry. Haematologica 2010; 95: 1300-1307.
5. Alter BP, Giri N, Savage SA, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010; 150: 179-188.
6. Alter BP. Cancer in Fanconi anemia, 1927-2001. Cancer 2003; 97: 425-440.
7. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961 a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the children's oncology group. Blood 2008; 111: 1044-1053.
8. Shaffer LG, Slovak ML, Campbell LJ. ISCN 2009: An International System for Human Cytogenetic Nomenclature. Basel: Karger; 2009. 138 p.
9. Rochowski A, Rosenberg PS, Alonzo TA, et al. Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy. Leukemia Res 2012; 36: 29-31.
10. Butturini A, Gale RP, Verlander PC, et al. Hematologic abnormalities in Fanconi anemia: An International Fanconi Anemia Registry study. Blood 1994; 84: 1650-1655.
11. Tonnies H, Huber S, Kuhl J-S, et al. Clonal chromosome aberrations in bone marrow cells of Fanconi anemia patients: Gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood 2003; 101: 3872-3874.
12. Mehta PA, Harris RE, Davies SM, et al. Numerical chromosomal changes and risk of development of myelodysplastic syndrome-acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet 2010; 203: 180-186.
13. Quentin S, Cuccuini W, Ceccaldi R, et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 2011; 117: e161-e170.
14. Meyer S, Bristow C, Wappett M, et al. Fanconi anemia (FA)-associated 3q gains in leukemic transformation consistently target EVI1, but do not affect low TERC expression in FA. Blood 2011; 117: 6047-6050.